Novartis AG

Official Company Name: Novartis AG

Stock Symbol: NOVNEE

Stock Market: Swiss Exchange - SIX

Currency: Swiss franc - CHF

Novartis Company Profile

NOVNEE Stock Price - 1 Year Price Evolution & Moving Averages

1 Year Return

▲+5.86%

Daily closing prices, with moving averages and volumes - Swiss franc (CHF)
Moving averages:

— EMA20
— SMA50
— SMA200

Novartis Categories

Switzerland Healthcare Drug Manufacturers—General

Healthcare

Drug Manufacturers—General

Company Description

Novartis AG is a global healthcare company that researches, develops, manufactures, and markets healthcare products. It operates through two segments: Innovative Medicines, offering prescription drugs across various therapeutic areas, and Sandoz, which develops, manufactures, and markets finished dosage form medicines, and provides active pharmaceutical ingredients, biosimilars, and biotechnology manufacturing services. Novartis collaborates with various entities to enhance its product offerings.

Novartis Company Profile

NOVNEE Stock Data

Open	CHF91.49
High	CHF91.49
Low	CHF91.28
Close	CHF91.28
Volume	19,000
Previous Close	CHF90.85
1-Day Change	0.43
1-Year Change	5.05
Average Daily Volume	288,601
52-Week High	CHF102.58
52-Week Low	CHF84.19

Disclaimer

All information and data available on Disfold is NOT FINANCIAL ADVICE. Invest at your own risk!

Past performance is not a guarantee of future performance. Patterns tend to repeat themselves, but they don't necessarily have to.

Successful backtests on past data do not guarantee the future success of the strategy backtested, especially as backtest overfitting may occur: when the price of a stock may fit particularly well a given trading strategy over a given period, but not necessarily outside of that period. Besides, backtests do not account for exact market conditions and may yield significantly different results in real trading practice (fees, slippage...).

Furthermore, even though Disfold strives to provide the best and most accurate data, errors can occur in Disfold's systems, or in our data providers' systems.

Please conduct your own due diligence to verify insights.